To the Editor: Sirolimus is a new, highly potent immunosuppressive drug1,2 that was recently licensed in the United States and is currently being evaluated in phase 3 clinical trials in Europe. The...
No takes yet. Share an insight, caveat, or question.
Morélon et al. (2000) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: